{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:33:18Z","timestamp":1792459998756,"version":"4.5.0"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,11,4]],"date-time":"2008-11-04T00:00:00Z","timestamp":1225756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This phase II study (<jats:italic>n<\/jats:italic>\u2003=\u200320) aimed to evaluate type, severity and duration of side\u2010effects and efficacy following subcutaneous (SC) alemtuzumab, without dose\u2010escalation, in advanced\u2010stage relapsed chronic lymphocytic leukaemia (CLL) patients. Alemtuzumab 30 and 3\u2003mg was administered SC simultaneously day 1, followed by 30\u2003mg three times per week. Injection\u2010site\u2010reactions were recorded every 6\u201324\u2003h until resolved using National Cancer Institute criteria and a new skin toxicity subscale. The first doses of 30\u2003mg and 3\u2003mg produced injection\u2010site\u2010reactions (all but one were grade 1\/2) in 13\/20 and 9\/20 patients, respectively. The second dose (on day 3) resulted in skin\u2010reactions in 10\/20 patients and the third, fourth, fifth and sixth injections produced reactions in 6\/20, 1\/20, 2\/20 and 0\/20 patients, respectively. Mild \u201cflu\u2010like\u201d symptoms occurred during week 1 in 10\/20 patients. All side\u2010effects had subsided by the sixth dose. 15\/20 patients (75%) responded (12 partial responses, three complete responses) with a median time\u2010to\u2010treatment\u2010failure of 20\u2003months. Symptomatic cytomegalovirus\u2010reactivation occurred in 6\/20 patients. Two deaths occurred: one bacterial pneumonia and one adenovirus\u2010infection. The present study showed how to assess cutaneous\u2010toxicity in detail and that 30\u2003mg alemtuzumab SC administered upfront was well tolerated. Optimized alemtuzumab therapy in properly selected patients may result in high efficacy even in advanced CLL. Our results need to be confirmed in extended studies.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07451.x","type":"journal-article","created":{"date-parts":[[2008,11,4]],"date-time":"2008-11-04T06:35:26Z","timestamp":1225780526000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced\u2010stage, relapsed chronic lymphocytic leukaemia"],"prefix":"10.1111","volume":"144","author":[{"given":"Claes","family":"Karlsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Moreton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,12,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9709"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute \u2010 Sponsored working group guidelines for chronic lymphocytic leukaemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson B.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-111781"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130120"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of Campath\u20101H antibody on human hematopoietic progenitors in vitro","volume":"82","author":"Gilleece M.H.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0593"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9098"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0159"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.049"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080010"},{"key":"e_1_2_8_14_1","first-page":"3","article-title":"Practical considerations for alemtuzumab therapy in B\u2010cell chronic lymphocytic leukaemia (B\u2010CLL)","volume":"11","author":"\u00d6sterborg A.","year":"2006","journal-title":"Cutting Edge"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.027"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200119"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20359"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"918A","DOI":"10.1182\/blood.V110.11.3121.3121","article-title":"Alemtuzumab as a single agent or combined with methylprednisolone (MPD) or fludarabine (FDR) for the treatment of CLL patients with p53 and ATM deletions","volume":"110","author":"Sebrango A.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"918A","DOI":"10.1182\/blood.V110.11.3120.3120","article-title":"Subcutaneous alemtuzumab (MabCampath) in fludarabine\u2010refractory CLL (CLL2H trial of the GCLLSG)","volume":"110","author":"Stilgenbauer S.","year":"2007","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07451.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07451.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T20:18:29Z","timestamp":1695932309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07451.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,9]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07451.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07451.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,9]]},"assertion":[{"value":"2008-12-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}